DCOYDecoy Therapeutics Inc.
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
5.6× less likely than average to be bought by an AI rollup
Pre-clinical biotech developing peptide conjugate and small molecule drug candidates; no revenue or products. Recurring revenue 0/10 · AI-rollup fit 0/10 · Services share 0/10 · Labor intensity 2/10 · Work AI could do 2/10 · Fragmented market 1/10 How it works
Signals 0 of 15
No signals fired.
15 other checks
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo$734K medianMedian CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo—Cash flow under 80% of net income
- Dilutive SBCNo—Over 10% of revenue
- Payouts exceed cash flowNo—Buybacks + dividends over cash flow
- Goodwill-heavyNo—Over 40% of assets
- Shareholder dissentNo—Any vote under 80% support
- Low revenue per employeeNo—Bottom quartile of its SIC industry
- Quiet on AINo—Bottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo—Market cap $500M–$5B
- Recurring revenueNo0 of 1010-K business scored 7+ of 10 for recurring revenue
- AI-rollup shapedNo0 of 1010-K business scored 5+ of 10 as an AI-rollup target
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo$0 netNet sales over $10M in 12 months
Financials
No XBRL financials yet.
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Nov 13, 2025 | 8-K | Salarius Pharmaceuticals | — | — |
| Sep 18, 2025 | 8-K | Salarius Pharmaceuticals, Inc. | — | — |
| Jul 29, 2025 | 8-K | Salarius Pharmaceuticals, Inc. | — | — |
| Jul 21, 2025 | 8-K | Salarius Pharmaceuticals, Inc. | — | — |
| Jun 11, 2025 | 8-K | Salarius Pharmaceuticals, Inc. | — | — |
| Mar 28, 2025 | 8-K | Salarius Pharmaceuticals, Inc. | — | — |
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $900K | $799K | 0 | — |
| FY2024 | $734K | $728K | 15 | — |
| FY2023 | $545K | $517K | 42 | — |